Erythropoiesis-Stimulating Agents: Anaemia of Kidney Disease and Chronic Illness
The kidney is not only a filter — it is a sensor. When it feels the blood running thin on oxygen, it releases a hormone that orders the marrow to build more red cells. Let the kidney fail, and that order never gets sent: the marrow goes quiet and the patient fades into exhaustion. This is the story of erythropoietin, the drugs that replace it, and the sharp lesson that with these agents more is not better — pushing the blood count too high can kill.
A 62-year-old woman on dialysis three days a week is grey with fatigue — too tired to cook, breathless climbing a single flight of stairs, her heart racing to push a thin blood around. Her iron stores are checked and topped up, and then a small injection begins each week. Over the following weeks the greyness lifts; her haemoglobin climbs from 78 to 105 g/L and, for the first time in a year, she walks to the shops. Her marrow was never broken — it was simply never told to work, because the kidney that once whispered the command had gone silent. But her doctor watches the number carefully and does NOT chase a "normal" count: that is where the danger lies.
The kidney as an oxygen sensor: where EPO comes from
Red cells are made in the marrow, but the marrow does not decide how many to make — the kidney does. Specialized cells in the kidney constantly measure the oxygen reaching them. When oxygen falls — from bleeding, altitude, or low haemoglobin — they release erythropoietin (EPO), a hormone that travels to the bone marrow and drives the production and survival of red-cell precursors. More EPO means more red cells, more oxygen carried, and eventually the kidney senses the correction and eases off. It is an elegant thermostat: hypoxia in, red cells out.
Now break the kidney. In chronic kidney disease (CKD) the failing organ still filters poorly, but it also loses its endocrine voice: it makes too little EPO for the degree of anaemia. The marrow is willing and the iron may be present, yet the signal to build is missing. The result is a characteristic normochromic, normocytic anaemia that worsens as kidney function declines — an anaemia you cannot cure with iron alone, because iron was never the bottleneck. The missing hormone is.
The CKD anaemia picture is textbook "normocytic, normochromic" with a LOW reticulocyte count — the marrow is quiet, not destroyed. Contrast this with iron deficiency (microcytic, hypochromic) or B12/folate deficiency (macrocytic). If a CKD patient's cells are small and pale, do not blame the kidney reflexively — look for a coexisting iron deficiency first.
The other blunting: anaemia of chronic disease and hepcidin
A second, overlapping mechanism appears whenever the body is chronically inflamed — infection, autoimmune disease, cancer, and CKD itself all qualify. Inflammation drives the liver to release hepcidin, the master iron-locking hormone. Hepcidin traps iron inside storage cells and blocks its absorption from the gut, so even a patient with plenty of stored iron cannot mobilize it to the marrow — a state called functional iron deficiency. At the same time, inflammatory signals blunt the marrow's response to EPO and shorten red-cell lifespan. The blood tests show a low serum iron but a HIGH or normal ferritin — iron is present but imprisoned.
A patient with long-standing rheumatoid arthritis is mildly anaemic. Iron studies show low serum iron but a normal-to-high ferritin — the classic anaemia of chronic disease. Giving oral iron here achieves little, because hepcidin is blocking its absorption and release. Treating the underlying inflammation (controlling the arthritis) does more for the anaemia than any haematinic, because it lowers hepcidin and frees the trapped iron.
- EPO is made by the kidney in response to hypoxia; it drives marrow red-cell production.
- CKD anaemia = too little EPO → normocytic, normochromic anaemia with low reticulocytes.
- Anaemia of chronic disease adds a second hit: hepcidin locks iron away (functional iron deficiency).
- In chronic disease iron is low in serum but ferritin is high/normal — iron present but imprisoned.
- Inflammation also blunts the marrow's response to EPO and shortens red-cell survival.
Replacing the missing signal: erythropoiesis-stimulating agents
If the problem is a missing hormone, the treatment is to supply it. Erythropoiesis-stimulating agents (ESAs) are laboratory-made versions of EPO or its longer-acting cousins. Epoetin alfa and epoetin beta are recombinant human erythropoietin — essentially the natural hormone, given by subcutaneous (SC) or intravenous (IV) injection, typically two to three times a week. Darbepoetin alfa is engineered with extra sugar chains that slow its clearance, so it lasts longer and is dosed roughly weekly or fortnightly. Methoxy polyethylene glycol-epoetin beta (a PEGylated, continuous erythropoietin receptor activator) is longer still, allowing dosing every two to four weeks. Their main uses are the anaemia of CKD and chemotherapy-induced anaemia in cancer patients.
A haemodialysis patient who is already in the unit three times a week can receive epoetin alfa IV at each session — convenient, because the access is already there. A patient with CKD not yet on dialysis, seen far less often, is better suited to darbepoetin alfa or methoxy-PEG-epoetin, whose long duration means an injection every few weeks rather than several a week. Same goal, different pharmacokinetics chosen to fit the patient's life.
The single most important rule with ESAs: the patient must be IRON-REPLETE first. An ESA orders the marrow to build red cells, but red cells are built from iron — if the raw material is missing, the drug fails no matter how high you dose it. Rapid ESA-driven erythropoiesis actually consumes iron faster than the body can release it, unmasking a functional iron deficiency. In practice, iron (often IV iron in dialysis patients) is given alongside the ESA, and iron indices are monitored throughout.
The cardinal danger: do not over-correct the haemoglobin
Here is the lesson that reversed early practice. It seems obvious that if a little anaemia is bad, restoring haemoglobin all the way to normal must be good. It is not. Large trials showed that aiming for a normal or near-normal haemoglobin with ESAs INCREASED the risk of thrombosis, stroke, worsening hypertension, and death — and in cancer patients, faster tumour progression and shortened survival. A thicker, more viscous blood and the hormone's own vascular effects raise clot and pressure risk; in tumours, EPO receptors may fuel growth. The modern target is deliberately modest: relieve symptoms and avoid transfusion, keeping haemoglobin around 100–120 g/L — not normal.
Our dialysis patient's haemoglobin has reached 108 g/L and her fatigue is gone. It is tempting to keep pushing the dose toward a "normal" 140. The evidence says stop: hold the target in the 100–120 range, and if the number drifts above the ceiling, reduce or withhold the ESA. Her rising blood pressure is monitored at every visit, because ESA-induced hypertension is common and can be severe. Better a comfortable patient at 110 than a normal number bought with a stroke.
- ESAs: epoetin alfa/beta (recombinant EPO), darbepoetin alfa (longer), methoxy-PEG-epoetin (longest).
- Given SC or IV for CKD anaemia and chemotherapy-induced anaemia.
- Ensure iron repletion first — ESAs need iron as raw material or they fail.
- Target a modest Hb (~100–120 g/L), NOT normal — over-correction causes harm.
- Over-correction risks: thrombosis, stroke, hypertension, and (in cancer) tumour progression/mortality.
- Monitor blood pressure and haemoglobin at every visit.
A newer route and a darker one: HIF-PHIs and EPO abuse
Instead of injecting the hormone, can we trick the body into making its own? That is the idea behind the HIF-prolyl-hydroxylase inhibitors (HIF-PHIs), such as roxadustat. In health, an enzyme called prolyl hydroxylase constantly tags and destroys hypoxia-inducible factor (HIF), the switch that turns on the EPO gene — so EPO stays low when oxygen is fine. Block that enzyme and HIF survives; the body "thinks" it is hypoxic and raises its own endogenous EPO, while also improving iron handling. These are ORAL agents — an appealing pill alternative to injections for CKD anaemia — though they carry the same imperative not to over-correct.
The same power that rescues a dialysis patient tempts endurance athletes. Injecting EPO (or "blood doping") raises red-cell mass and oxygen delivery, boosting stamina in cycling, distance running and cross-country skiing — which is why it is banned. The danger is exactly the over-correction we warn against clinically: an athlete who thickens the blood too far, especially when dehydrated, risks catastrophic thrombosis — heart attack, stroke, and sudden death have been linked to EPO abuse. The drug does not distinguish an athlete's ambition from a patient's need; the physiology of viscous blood is unforgiving to both.
- Starting an ESA in an iron-deficient patient. It will not work — correct the iron first, or the marrow has no raw material.
- Chasing a normal haemoglobin. Over-correction raises thrombosis, stroke, hypertension and mortality — aim ~100–120 g/L.
- Ignoring a rising blood pressure. ESA-induced hypertension is common and can be dangerous; monitor it.
- Blaming CKD for a microcytic anaemia. CKD anaemia is normocytic — small pale cells mean a coexisting iron deficiency.
A patient with CKD anaemia is started on epoetin alfa but the haemoglobin barely rises after several weeks. What is the most likely reason?
- The kidney senses hypoxia and releases EPO to drive red-cell production; CKD makes too little EPO → anaemia.
- In chronic inflammation, hepcidin locks iron away and the EPO response is blunted (anaemia of chronic disease).
- ESAs (epoetin, darbepoetin, methoxy-PEG-epoetin) replace EPO for CKD and chemo anaemia — ensure iron repletion first.
- Never over-correct: target Hb ~100–120 g/L; higher risks thrombosis, stroke, hypertension, tumour progression.
- HIF-PHIs (roxadustat) are oral agents that raise endogenous EPO; EPO abuse (blood doping) in sport is dangerous and banned.
- Katzung BG. Basic & Clinical Pharmacology — Agents Used in Anemias: erythropoietin & erythropoiesis-stimulating agents.
- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease — haemoglobin targets, ESA use & iron therapy.
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Hematopoietic agents: erythropoietin.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Haemopoietic growth factors & the anaemia of chronic disease (hepcidin).
- Weiss G, Goodnough LT. Anemia of Chronic Disease. New England Journal of Medicine — hepcidin & functional iron deficiency.
